Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001683168-21-000560
Filing Date
2021-02-16
Accepted
2021-02-16 08:30:08
Documents
4
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDED ANNUAL REPORT cns_10ka1-123120.htm 10-K/A 50889
2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM cns_ex2301.htm EX-23.1 2741
3 CERTIFICATION BY OFFICER cns_ex3103.htm EX-31.3 3485
4 CERTIFICATION BY OFFICER cns_ex3104.htm EX-31.4 3120
  Complete submission text file 0001683168-21-000560.txt   61266
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39126 | Film No.: 21632812
SIC: 2834 Pharmaceutical Preparations